EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging Strategies in Lung Cancer Screening: Blood and Beyond

Sheena Bhalla, Sofia Yi, David E Gerber

Clinical Chemistry · 2024

DOI: 10.1093/clinchem/hvad137 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Sheena Bhalla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Division of Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, United States. Hauptthemen laut MEDLINE: Lung Neoplasms, Body Fluids, MicroRNAs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Although low dose computed tomography (LDCT)-based lung cancer screening (LCS) can decrease lung cancer-related mortality among high-risk individuals, it remains an imperfect and substantially underutilized process. LDCT-based LCS may result in false-positive findings, which can lead to invasive procedures and potential morbidity. Conversely, current guidelines may fail to capture at-risk individuals, particularly those from under-represented minority populations. To address these limitations, numerous biomarkers have emerged to complement LDCT and improve early lung cancer detection. Content This review focuses primarily on blood-based biomarkers, including protein, microRNAs, circulating DNA, and methylated DNA panels, in current clinical development for LCS. We also examine other emerging biomarkers—utilizing airway epithelia, exhaled breath, sputum, and urine—under investigation. We highlight challenges and limitations of biomarker testing, as well as recent strategies to integrate molecular strategies with imaging technologies. Summary Multiple biomarkers are under active investigation for LCS, either to improve risk-stratification after nodule detection or to optimize risk-based patient selection for LDCT-based screening. Results from ongoing and future clinical trials will elucidate the clinical utility of biomarkers in the LCS paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsBody FluidsMicroRNAsHumansEarly Detection of CancerBiomarkers

Substanzen

MicroRNAsBiomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine (Division of Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, United States.
  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States.
  • School of Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
  • Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Bhalla, S., Yi, S., & Gerber, D. E. (2024). Emerging Strategies in Lung Cancer Screening: Blood and Beyond. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad137

Vancouver

Bhalla S, Yi S, Gerber DE. Emerging Strategies in Lung Cancer Screening: Blood and Beyond. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvad137

BibTeX
@article{Bhalla2024,
  author = {Bhalla, Sheena and Yi, Sofia and Gerber, David E},
  title = {Emerging Strategies in Lung Cancer Screening: Blood and Beyond},
  journal = {Clinical Chemistry},
  year = {2024},
  doi = {10.1093/clinchem/hvad137}
}
Kostenlos starten →